Private Equity

Healthcare

LYFE Capital: Bridging the cultural divide to unlock Japan’s rising investment opportunities

The Japanese market is drawing a lot of attention right now, but integrating into the local community takes time, says LYFE Capital founder and partner James Zhao.

7 min read · 01 April 2026

Next Gen alumni on the future of GP-led secondaries

From CVs on CVs to greater specialisation, secondaries professionals who have previously featured on our rising stars list share their insights on the market’s evolution.

6 min read · 05 March 2026

Japanese healthcare pioneer opens sophomore fund to global LPs

NPMI Fund II could be six times larger than its predecessor, PEI understands.

2 min read · 03 March 2026

Meet Japan’s next generation of emerging managers

From Japan Post Bank’s former private equity head to a buyout shop delivering 4.4x, PEI presents a rundown of seven managers you should probably get to know.

7 min read · 11 February 2026

Fundraising for Vivo Capital’s 10th fund stretches into the fourth year

Last year, the firm closed its third cycle of the evergreen fund dubbed Vivo Opportunity Fund with over $740m in commitments.

2 min read · 28 January 2026

VC doyen Battery Ventures seeks $3.2bn for latest flagship

The fund comes three years after the firm raised $3.3bn for its 14th flagship.

2 min read · 21 January 2026

Vistria raises $675m for debut multi-asset CV transaction

Kip Kirkpatrick, senior partner, co-chairman and co-CEO at Vistria, told Buyouts the CV deal was a win-win for all the parties involved, including LPs.

3 min read · 20 January 2026

SEA specialist Quadria adds Middle East to investment mandate

The healthcare investor aims to deploy 15-20% of its latest flagship into assets in the Gulf region, head of South Asia Sunil Thakur tells PEI.

3 min read · 17 December 2025

Chinese healthcare specialist GL Capital seeks $800m for next flagship

GL’s fundraise coincides with the September close of a $240m single-asset continuation fund backed by the Abu Dhabi Investment Authority.

3 min read · 26 November 2025

Royalty finance comes of age

In a rebounding biotech market, royalty finance can play a far more strategic role, provided it’s executed with disciplined underwriting, smart structuring and a genuine partnership with innovators, according to Ryan Murr, a partner at Gibson, Dunn & Crutcher.

5 min read · 19 November 2025

Showing 41 to 50 of 190 results
1…46…19